- Home
- RIGL vs GTN Comparison
RIGL vs GTN Comparison
Compare RIGL & GTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | GTN |
|---|---|---|
| Founded | 1996 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 537.6M | 468.6M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | RIGL | GTN |
|---|---|---|
| Price | $44.01 | $4.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $43.20 | $7.60 |
| AVG Volume (30 Days) | 506.3K | ★ 1.1M |
| Earning Date | 11-04-2025 | 11-07-2025 |
| Dividend Yield | N/A | ★ 6.49% |
| EPS Growth | ★ 2698.26 | N/A |
| EPS | ★ 6.20 | 0.43 |
| Revenue | $282,076,000.00 | ★ $3,348,000,000.00 |
| Revenue This Year | $65.53 | N/A |
| Revenue Next Year | $0.22 | $13.42 |
| P/E Ratio | ★ $7.10 | $11.47 |
| Revenue Growth | ★ 79.13 | N/A |
| 52 Week Low | $15.50 | $2.93 |
| 52 Week High | $52.24 | $6.31 |
Technical Indicators
Market Signals| Indicator | RIGL | GTN |
|---|---|---|
| Relative Strength Index (RSI) | 53.60 | 49.64 |
| Support Level | $40.52 | $4.78 |
| Resistance Level | $44.85 | $5.00 |
| Average True Range (ATR) | 2.33 | 0.23 |
| MACD | -0.27 | -0.02 |
| Stochastic Oscillator | 51.26 | 34.54 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About GTN Gray Television Inc.
Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios.